Indications
Segluromet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control: in patients not adequately controlled on their maximally tolerated dose of metformin alone in patients on their maximally tolerated doses of metformin in addition to other medicinal products for the treatment of diabetes in patients already being treated with the combination of ertugliflozin and metformin as separate tablets.
Composition
- Active substance
- ertugliflozin l-pyroglutamic acid, metformin hydrochloride
- International name (INN)
- ertugliflozin;metformin hydrochloride
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Segluromet
- Active substance
- ertugliflozin l-pyroglutamic acid, metformin hydrochloride
- ATC code
- A10BD23